Recent Publications

Schilder RJ, MW Sill, RB Lee, TJ Shaw, MK Senterman, AJP Klein-Szanto, Z Miner and BC Vanderhyden (2008) A Phase II evaluation of imatinib methylate in the treatment of recurrent or persistent ovarian or primary peritoneal carcinoma. (J. Clin. Onc., in press)

Shaw TJ, EC Lacasse, JP Durkin and BC Vanderhyden (2008). Down-regulation of XIAP expression in ovarian cancer cells induces apoptosis in vitro and in vivo. Int. J. Cancer 122: 1430-1434.

Thomas FH, RS Ismail J-Y Jiang and BC Vanderhyden (2008). Kit ligand 2 promotes murine oocyte growth in vitro. Biol. Reprod. 78: 167-175.

Salehi F, LD Dunfield, KP Phillips, D Krewski and B Vanderhyden (2008). Risk factors for ovarian cancer: An overview with emphasis on hormonal factors. J.Toxicol. Environ. Health, Part B, 11: 301-321.

Shaw TJ and BC Vanderhyden (2007). AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. Gynecol. Oncol. 105:122–131.

Clark-Knowles KV, K Garson, J Jonkers and BC Vanderhyden (2007). Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp. Cell Res. 313: 133-145.

Thomas FH and BC Vanderhyden (2007). Oocyte growth and developmental competence. In: In-vitro Maturation of Human Oocytes: From Basic Science to Clinical Application. SL Tan, RC Chiang and WM Buckett (Eds.). Informa Healthcare, Abingdon, UK, pp 1-14.

Pépin D, BC Vanderhyden, DJ Picketts and BD Murphy (2007). ISWI chromatin Remodeling in Ovarian Somatic and Germ Cells: Revenge of the NURFs. Trends Endocrinol. Metab. 18: 215-224.

Chambers AF and BC Vanderhyden (2006). Ovarian cancer biomarkers in urine. (Commentary). Clinical Cancer Research 12: 323-327.

Lazzaro MA, D Pépin, N Pescador, BD Murphy, BC Vanderhyden and DJ Picketts (2006). The ISWI protein SNF2L regulates steroidogenic acute regulatory protein (StAR) expression during terminal differentiation of ovarian granulosa cells. Mol. Endocrinol. 20: 2406-2417.

Thomas FH and BC Vanderhyden (2006). Oocyte-granulosa cell interactions during mouse follicular development: regulation of Kit ligand expression and its role in oocyte growth. Reprod. Biol. and Endocrinology, Apr 12; 4: 19.

Gilks CB, BC Vanderhyden, S Zhu, M van de Rijn, TA Longacre (2005). Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gyn. Oncol. 96: 684-694

Vanderhyden BC (2005). Loss of ovarian function and the risk of ovarian cancer. Cell and Tissue Research. 322: 117-124.

Garson K, TJ Shaw, KV Clark, DS Yao and BC Vanderhyden (2005). Models of ovarian cancer—Are we there yet? Mol. Cell. Endocrinol. 239: 15-26.

Steller M, TJ Shaw, BC Vanderhyden and J-F Ethier (2005). Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol. Cancer Res. 3: 50-61.

Gittens JEI, KJ Barr, BC Vanderhyden and GM Kidder (2005). Interplay between paracrine signalling and gap junctional communication in ovarian follicles. J. Cell Sci. 118: 113-122.

Thomas FH, J-F Ethier, S Shimasaki and BC Vanderhyden (2005). Follicle-stimulating hormone regulates oocyte growth by modulation of expression of oocyte and granulosa cell factors. Endocrinology 146: 941-949.

Shaw TJ, MK Senterman, K Dawson, CA Crane and BC Vanderhyden (2004). Characterization of intra-peritoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Therapy 10: 1032-1042.

Hamilton TC, DC Connolly, AY Nikitin, K Garson and BC Vanderhyden (2003). Translational research in ovarian cancer: A must. Int. J. Gynecol. Cancer 13 (Suppl. 2): 220-230.

Vanderhyden BC, EA Macdonald, E Nagyova and A Dhawan (2003). Evaluation of members of the TGFß superfamily as candidates for the oocyte factors that control cumulus expansion and steroidogenesis. Reproduction, Supplement 61: 55-70.

Vanderhyden BC, TJ Shaw and JF Ethier (2003). Animal Models of Ovarian Cancer. Reprod. Biol. and Endocrinology, 1: 67-77.

Vanderhyden BC, TJ Shaw, K Garson and AM Tonary. (2003). Ovarian Carcinogenesis. In: The Ovary, 2nd Edition. PCK Leung and EY Adashi (Eds.), Elsevier Academic Press, San Diego, California, pp 591-612.

Garson K, EA Macdonald, M Dubé, R. Bao, TC Hamilton and BC Vanderhyden (2003). Generation of tumors in transgenic mice expressing the SV40 T antigen under control of OSP-1 (Ovarian Specific Promoter 1). J. Soc. Gyn. Invest. 10: 244-250.

Bailey DH, DC Connolly, BC Vanderhyden, K Garson and TC Hamilton (2002). Ovarian Cancer Models. Published on the Mouse Models of Human Cancers Consortium.

Vanderhyden BC (2002). Molecular basis of ovarian development and function. Frontiers in Bioscience 7: 2006-2022.

Vanderhyden BC. (2002). Oocyte-granulosa cell interactions. In: Cell-cell interactions: A Practical Approach. TP Fleming (Ed.). Oxford University Press.

Shaw TJ, EJ Keszthelyi, AM Tonary, M Cada and BC Vanderhyden (2002). Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-kit expression. Exp. Cell Res. 273: 95-106.